Home›Trial›NCT05883748
🔬NCT05883748Phase 2Phase 3ENROLLING BY INVITATION

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Study Summary

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Conditions
Erythropoietic Protoporphyria
Interventions / Drugs
DISC-1459DISC-1459
View on ClinicalTrials.gov ↗
Sponsor
IRON
Disc Medicine
Hematology
C52/100
Study Details
Enrollment230 participants
Primary Completion—
Lead SponsorDisc Medicine, Inc
Data Retrieved2026-04-11 04:18:08.225414+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.